Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-21-052395

Chief R&D Officer sold 7,662 shares at $13.83 ($105,965)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2021-08-16 Sale : show line 1 in the form −7,662 $13.83 $105,965 212,803 D
Open-market sales · 7,662 sh · avg $13.83 · $105,965
Loading xslF345X03/doc4.xml…